ARTICLE BY LOUIS

• Does Biotech Need More Government Funding — Or A New Business Model?

  3/30/2026

  Should government financing appreciably recede – whether through policy shifts, budget pressures, or ideological bent – what would happen to the biotech business model? To ascertain such a question, first we must look at the fundamentals of the existing model, and then understand investors (and service providers) better.

• What If The U.S. Government Stopped Funding Biotech?

  3/23/2026

  It sets off a real tension – ideological, economic, even personal. But what would happen if the U.S. government cut direct financial support for “biotechnology research,” leaving it entirely to investors, private and public markets, and bigger pharma? "Our industry’s mind-meld says with no government largesse our biotech industry collapses," writes Chief Editor Louis Garguilo. It's an "outlandish hypothetical," but he asks for a few minutes to go through this. And he has help in making his case.

• A Supply-Chain Woman Of Iran

  9/23/2024

  Arezou Mehrabi has a spellbinding supply-chain case study. It transpired, of all places, in Iran. It includes major challenges in outsourcing manufacturing to a partner CDMO for a top-ten pharma (Sanofi, to be exact). Our protagonist is a woman who took leadership within a male-dominated workplace, country, and entire region. 

• An Outsourcing Future Of Information Sharing And Commercial Streamlining

  12/1/2023

  Outsourced Pharma Chief Editor Louis Garguilo writes about what outsourcing professionals think about the future of working with CDMOs.

• Your Consultants, Your Destiny

  7/3/2023

  Have consultants become more important than ever in pharma manufacturing? Louis Garguilo, Chief Editor, Outsourced Pharma, talks with three experts who have strong opinions on this question.

• Is Technology The New Science Of Outsourcing?

  5/4/2023

  That’s the abstruse thought with which I left the 2023 CDMO Leadership Awards ceremony in Manhattan. I’ve subsequently tried to sort this out by referring back to a series of interviews I did with CDMO leaders at the event. I think now I can explain this to readers. 

• A Real Celebration Of The Best CDMOs

  3/1/2023

  This annual issue presenting our readers with the best-of-the-best CDMOs is once again accompanied by a live celebration in Manhattan. However, in two ways the 2023 Awards differ from those of the past.

• Gene Therapy Developer Rocket Pharma Aims High

  3/1/2023

  “From our first patient until now, all our manufactured drug product that has treated patients has been produced in partnership with CDMOs,” says Gaurav Shah, M.D., cofounder and CEO of Rocket Pharma.

• A More Balanced And Stable Future With CDMOs

  12/1/2022

  Two Industry Experts talk about where they see the outsourcing industry going in the near future.

• Safe At Home With Generics

  7/13/2022

  “I have not wanted to go to India or China for most of my API needs, and to the extent possible I do not want to go there for formulations either,” is part of a surprising sentiment from a long-tenured generics outsourcing professional.